ChemDiv has entered into a three-way co-development agreement with Context Therapeutics and Torrey Pines Investment to advance research and development in the area of Sigma1 dysfunction associated with early onset neurodegenerative diseases. Under the terms of the collaboration, ChemDiv will grant Context the access to its unique integrated discovery platform, while Torrey Pines Investment will invest in Context and provide network resources to support pre-commercial research and development.
Context has been engaged in the advancement of an alternative approach to treatment of various diseases in the fields of oncology and neurology that targets Sigma1, an essential regulator of mechanisms and pathways of cellular protein homeostasis, trafficking, and immune system regulation. Within the framework of this partnership, ChemDiv will capitalize on its comprehensive resources and extensive experience in modern drug discovery to help Context expand its pipeline of treatments against Sigma1 mutations that are associated with severe early onset neurodegenerative diseases, such as ALS and Alzheimer's.
"Sigma1 provides a very exciting new R&D target that could offer an alternative to those patients whose needs cannot be met with existing treatments," Martin Lehr, Co-Founder and CEO at Context Therapeutics said. "We are looking forward to the fruits of this collaboration, and hope that our collective efforts will streamline the development of a potent cure for Sigma1 associated neurodegenerative diseases around the globe."